Severe form of von Willebrand disease
Conditions
Interventions
Trade Name: Haemate-P, Wilate
The present study is not restricted to any specific product.
Product Name: VWD factor VIII concentrate
Product Code: Factor VIII
Pharmaceutical Form: Intravenous infusio
Sponsors
Centre of Thrombosis and Haemostasis
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 1 and type 2 von Willebrand disease =20% RCo and/or =20% FVIII DDAVP non-responsive Bleeding indication criteria are met Type 3 bleeding indication criteria are met Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Acquired von Willebrand disease History of inhibitory antibodies to VWF Already on prophylaxis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Study prophylaxis in von Willebrand disease;Secondary Objective: Feasibility, adverse events, quality of life, health economy;Primary end point(s): Bleeding pattern in the year prior to prophylaxis compared to bleeding pattern during prophylaxis. | — |
Countries
Sweden
Outcome results
None listed